Search This Blog

Monday, April 7, 2025

3 ways the media coverage of health care is dishonest

 by Vinay Prasad

Here are 3 ways the media coverage of medicine and health policy is dishonest.

First, the media keeps talking about mass lay-offs but does not put this into the context of HHS growth over time. A reader sent me the figure I was asking for. HHS staffing by year.

Image

I would not have truncated the y axis, but the point is clear. The recent cuts merely reduce the bloated agency to earlier staffing levels.

Second, this is White House guidance for what NIH grants to cut

Image

It all seems reasonable to me. Issues that the voters directly voted upon. I would cut most of these as well. Vaccine hesitancy is an important issue, but most current researchers are not studying it honestly. They do not consider the impact of the unethical Biden vaccine mandates on public trust.

Finally, this was cut off from my last post

This issue remains entirely undiscussed in the media.

https://www.drvinayprasad.com/p/3-ways-the-media-coverage-of-health

Iran-backed militias in Iraq ready to disarm to avert Trump wrath

 Several powerful Iranian-backed militia groups in Iraq are prepared to disarm for the first time to avert the threat of an escalating conflict with the U.S. Trump administration, 10 senior commanders and Iraqi officials told Reuters.

The move to defuse tensions follows repeated warnings issued privately by U.S. officials to the Iraqi government since Trump took power in January, according to the sources who include six local commanders of four major militias.

The officials told Baghdad that unless it acted to disband the militias operating on its soil, America could target the groups with airstrikes, the people added.

Izzat al-Shahbndar, a senior Shi'ite Muslim politician close to Iraq's governing alliance, told Reuters that discussions between Prime Minister Mohammed Shia al-Sudani and several militia leaders were "very advanced", and the groups were inclined to comply with U.S. calls for disarmament.

"The factions are not acting stubbornly or insisting on continuing in their current form," he said, adding that the groups were "fully aware" they could be targeted by the U.S.

The six militia commanders interviewed in Baghdad and a southern province, who requested anonymity to discuss the sensitive situation, are from the Kataib Hezbollah, Nujabaa, Kataib Sayyed al-Shuhada and Ansarullah al-Awfiyaa groups.

"Trump is ready to take the war with us to worse levels, we know that, and we want to avoid such a bad scenario," said a commander of Kataib Hezbollah, the most powerful Shi'ite militia, who spoke from behind a black face mask and sunglasses.

The commanders said their main ally and patron, Iran's elite Revolutionary Guards (IRGC) military force, had given them its blessing to take whatever decisions they deemed necessary to avoid being drawn into a potentially ruinous conflict with the United States and Israel.

The militias are part of the Islamic Resistance in Iraq, an umbrella group of about 10 hardline Shi'ite armed factions that collectively command about 50,000 fighters and arsenals that include long-range missiles and anti-aircraft weapons, according to two security officials who monitor militias' activities.

The Resistance group, a key pillar of Iran's network of regional proxy forces, have claimed responsibility for dozens of missile and drone attacks on Israel and U.S. forces in Iraq and Syria since the Gaza war erupted about 18 months ago.

Farhad Alaaeldin, Sudani's foreign affair adviser, told Reuters in response to queries about disarmament talks that the prime minister was committed to ensuring all weapons in Iraq were under state control through "constructive dialogue with various national actors".

The two Iraqi security officials said Sudani was pressing for disarmament from all the militias of the Islamic Resistance in Iraq, which declare their allegiance to Iran's IRGC or Quds Force rather than to Baghdad.

Some groups have already largely evacuated their headquarters and reduced their presences in major cities including Mosul and Anbar since mid-January for fear of being hit by air attacks, according to officials and commanders.

Many commanders have also stepped up their security measures in that time, changing their mobile phones, vehicles and abodes more frequently, they said.

The U.S. State Department said it continued to urge Baghdad to rein in the militias. "These forces must respond to Iraq's commander-in-chief and not to Iran," it added.

An American official, speaking on the condition of anonymity, cautioned that there had been instances in the past when the militias had ceased their attacks because of U.S. pressure, and was sceptical any disarmament would be long-term.

The IRGC declined to comment for this article while the Iranian and Israeli foreign ministries didn't respond to queries.

SHAKEN: IRAN'S AXIS OF RESISTANCE

Shahbndar, the Shi'ite politician, said the Iraqi government had not yet finalised a deal with militant leaders, with a disarmament mechanism still under discussion. Options being considered include turning the groups into political parties and integrating them into the Iraqi armed forces, he added.

While the fate of any disarmament process remains uncertain, the discussions nonetheless mark the first time the militias have been prepared to give ground to longstanding Western pressure to demilitarize.

The shift comes at a precarious time for Tehran's regional "Axis of Resistance" which it has established at great cost over decades to oppose Israel and U.S. influence but has seen severely weakened since Palestinian group Hamas' attack on Israel on October 7 2023 tipped the Middle East into conflict.

Hamas in Gaza and Hezbollah in Lebanon have been hammered by Israel since the Gaza war began while the Houthi movement in Yemen has been targeted by U.S. airstrikes since last month. The fall of Syrian President Bashar al-Assad, another key Iranian ally, has further weakened the Islamic Republic's influence.

Iraq is seeking to balance its alliances with both America and Iran in its dealing with the militias on its soil. The groups sprang up across the country with Iranian financial and military support in the chaotic wake of the 2003 U.S. invasion that toppled Saddam Hussein, and have become formidable forces that can rival the national army in firepower.

U.S. Secretary of Defence Pete Hegseth told Prime Minister Sudani in a phone call on March 16, shortly after the American strikes on the Houthis began, to prevent the militias carrying out revenge attacks on Israel and U.S. bases in the region in support of their allies, according to two government officials and two security sources briefed on the exchange.

The Iraqi-based militias had launched dozens of drone and rockets attacks against Israel in solidarity with Hamas since the Gaza war began and killed three U.S. soldiers in a drone operation in Jordan near the Syrian border last year.

Ibrahim al-Sumaidaie, a former political adviser to Sudani, told Iraqi state TV that the United States had long pressed Iraq's leadership to dismantle Shi'ite militias, but this time Washington might not take no for an answer.

"If we do not voluntarily comply, it may be forced upon us from the outside, and by force."

https://www.aol.com/news/exclusive-iran-backed-militias-iraq-050146971.html

Mexico aims to avoid reciprocal tariffs on U.S

 Mexico’s President Claudia Sheinbaum expressed her government’s desire to avoid imposing reciprocal tariffs on the United States on Monday. Despite this, she also acknowledged that such an action could not be completely dismissed.

This comes in response to President Trump’s recent warning that any country that retaliates against the U.S. by issuing additional tariffs will be met with new and substantially higher tariffs. This is part of his strategy to counter what he perceives as long term tariff abuse by other nations.

President Trump also announced that negotiations with countries seeking discussions will commence immediately. However, these talks will exclude China, as Trump intends to impose additional tariffs on the Asian nation. This is part of ongoing trade tensions between the two largest economies in the world.

https://www.investing.com/news/stock-market-news/mexico-aims-to-avoid-reciprocal-tariffs-on-us-amid-trade-tensions-93CH-3971591

Von der Leyen offers Trump 'zero-for-zero' tariffs deal on all industrial goods

 

"Europe is always ready for a good deal," Ursula von der Leyen says as trade tensions with the United States reach all-time high.

The European Commission has offered the United States a deal to remove tariffs on all industrial goods as part of the trade negotiations, Ursula von der Leyen has said while stressing her intention to retaliate against Donald Trump's policies should talks fail.

Trump has announced a 20% across-the-board tariff on imports from the European Union, set to take effect on 9 April. Steel, aluminum and cars are subject to a separate 25% rate. In total, over €380 billion in EU-made products will be affected.

Pharmaceuticals, copper, lumber, semiconductors and energy have been exempted.

"We stand ready to negotiate with the US. Indeed, we have offered zero-for-zero tariffs for industrial goods as we have successfully done with many other trading partners," the Commission president said on Monday afternoon.

"Because Europe is always ready for a good deal. So we keep it on the table. But we are also prepared to respond through countermeasures and defend our interests."

The "zero-for-zero" deal was offered in the past "repeatedly" for the automotive sector, von der Leyen said, "but there was no adequate reaction" from Washington.

The Commission expanded the pitch to all industrial goods in recent days as talks intensified, a spokesperson said. No further details were provided.

"We prefer to have a negotiated solution," von der Leyen said, warning her executive will use "all instruments" available to hit back "if necessary," including an anti-coercion instrument that was introduced in 2023 but which has never been triggered.

Von der Leyen described Trump's sweeping tariffs as a "major turning point for the United States" that would have "immense costs" for American consumers and businesses alike and deliver a "massive" blow to the global economy.

While Washington has described the tariffs as "reciprocal", Brussels has dismissed its logic as "neither credible nor justified".

Besides the immediate impact on EU-US trade flows, which puts billions at risk of being wiped off, the Commission is also concerned about the potential ramifications that Trump's decision will have on international commerce – in particular on Asia.

Asian countries have been hit with higher rates than the bloc: 24% for Malaysia, 26% for India, 32% for Indonesia, 36% for Thailand, 46% for Vietnam, 48% for Laos and 49% for Cambodia, among others. China was slapped with a 34% "reciprocal" tariff on top of a previous 20% rate, for a whopping 54% in total. (Beijing has already hit back.)

The levels are so prohibitive that Brussels fears Asian countries, whose economies depend on exports, will be locked out of the American market and reroute their products to Europe as an alternative. China is a particular cause of concern, as it is already under intense scrutiny for flooding the West with low-cost, heavily subsidised goods.

During her intervention on Monday, von der Leyen announced the creation of a new "task force" to closely monitor the changes in global commerce.

"We will also protect ourselves against indirect effects through trade diversion. For this purpose, we will set up an 'Import Surveillance Task Force'," she said. "We look at what are the historical imports that we have and had and (whether) there is any specific surge all of a sudden of a certain product or in a certain sector that we have to act on."

https://www.euronews.com/my-europe/2025/04/07/von-der-leyen-offers-trump-zero-for-zero-tariffs-deal-on-all-industrial-goods

ALX Oncology advances new cancer drug into Phase 1

 ALX Oncology Holdings Inc. (NASDAQ:ALXO), a biotech firm focused on cancer immunotherapies, has announced the U.S. Food and Drug Administration (FDA) clearance for an Investigational New Drug (IND) application for ALX2004, a novel antibody-drug conjugate (ADC) aimed at treating solid tumors expressing the epidermal growth factor receptor (EGFR). The company plans to commence Phase 1 clinical trials of ALX2004 in mid-2025, with initial safety data expected in the first half of 2026. ALX Oncology maintains a strong liquidity position with a current ratio of 7.26, indicating robust short-term financial stability as it advances its clinical programs.

ALX2004 represents the company’s first ADC and the first drug candidate to emerge from its proprietary linker-payload platform. The molecule has been designed to deliver chemotherapy directly to tumor cells, potentially reducing systemic toxicity. In preclinical models, ALX2004 showed potent anti-tumor activity, suggesting it could be a significant addition to ALX Oncology’s clinical pipeline.

The company’s CEO, Jason Lettmann, highlighted the meticulous design of ALX2004, which includes an antibody backbone, a stable linker, and a proprietary topoisomerase I inhibitor payload. This design aims to optimize the targeted delivery and enhance the bystander effect, which may improve outcomes for patients with EGFR-expressing tumors. The company’s development efforts are supported by a debt-to-equity ratio of 0.15, reflecting a conservative financial structure. 

EGFR overexpression is common in several tumor types, including breast cancer, colorectal carcinoma, and non-small cell lung cancer. EGFR has been clinically validated as a therapeutic target with several FDA-approved antibodies and small molecules. However, there are no approved EGFR-targeted ADCs currently on the market due to previous limitations in drug design and toxicities.

https://www.investing.com/news/company-news/alx-oncology-advances-new-cancer-drug-into-phase-1-trials-93CH-3970563

Allogene gets triple fast track



Allogene Therapeutics (ALLO) has received three FDA Fast Track Designations for ALLO-329, a next-generation dual-targeted CD19/CD70 allogeneic CAR T therapy. The designations cover treatments for systemic lupus erythematous (SLE), idiopathic inflammatory myopathy (IIM), and diffuse systemic sclerosis (SSc).

The company plans to initiate the Phase 1 RESOLUTION basket trial in mid-2025, with initial proof-of-concept expected by year-end 2025. The trial will evaluate ALLO-329's safety and preliminary efficacy using the proprietary Dagger® technology, which aims to reduce or eliminate lymphodepletion requirements. The study includes two lymphodepletion arms: one using cyclophosphamide alone and another without lymphodepletion.

Roche preps phase 3 for 'Brainshuttle' Alzheimer's drug

 Buoyed by new results from a phase 1b/2a trial, Roche has said it plans to start a phase 3 programme for an Alzheimer's disease candidate from its Brainshuttle programme, a technology designed to help large molecules enter the central nervous system.

The drug, called trontinemab, showed in the study that it could achieve rapid and deep reductions in amyloid beta plaques in the brain, one of the characteristics of Alzheimer's. Roche said its profile suggests it could offer an advance on the current generation of amyloid-targeting drugs.

It also validates the company's Brainshuttle antibody engineering platform, which adds a "side chain" to antibodies that binds to receptors on the blood-brain barrier (BBB) – designed to protect the brain from toxins and pathogens – and allows them to make it into the CNS.

It has been found that less than 1% of some anti-amyloid antibodies end up in the CNS where they can exert their activity, but Roche has estimated that it can improve that by 50 times or more.

Preliminary results from the 111-subject study revealed that a 3.6mg/kg dose of trontinemab reduced amyloid levels below the 24 centiloid threshold – a commonly used cutoff point used to predict whether a patient is likely to go on to develop Alzheimer's dementia – in 81% of participants after 28 weeks.

"Based on data in the field, both the speed of amyloid lowering, and the ability to lower below the amyloid positivity threshold early on, are important to achieve clinically meaningful benefit in early Alzheimer's disease," said Roche in a statement on the results, which were presented at the International Conference on Alzheimer's and Parkinson's Diseases in Vienna, Austria.

The reduction in amyloid was accompanied by reductions in cerebrospinal fluid (CSF) and plasma of other biomarkers of Alzheimer's, including total tau, phosphorylated Tau (pTau181 and pTau217), and neurogranin.

Moreover, trontinemab was also associated with a lower rate of an amyloid-related imaging abnormality (ARIA) side effect, brain swelling, than the two approved anti-amyloid drugs – Eisai/Biogen's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab). ARIA was seen in less than 5% of patients treated with trontinemab, with all cases mild and all but one asymptomatic.

Roche has been attempting to develop an Alzheimer's drug for some time, and its first attempts with two other anti-amyloid antibodies – crenezumab and gantenerumab – ended in failure.

Since then, the launch of Leqembi and Kisunla has renewed interest in the anti-amyloid approach, although early take-up of the new drugs has been slow due to their modest efficacy and potential to cause serious side effects.

https://pharmaphorum.com/news/roche-preps-phase-3-brainshuttle-alzheimers-drug